Global antiphospholipid syndrome score (GAPSS) in patients with systemic lupus erythematosus
Introduction. The Global Antiphospholipid Syndrome Score (GAPSS) is a tool proposed to quantify the risk of clinical manifestations associated with antiphospholipid antibodies (aPL) and certain cardiovascular risk factors.Objective. To validate GAPSS in a cohort of patients with systemic lupus eryth...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2022-11-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/3221 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849400950816505856 |
|---|---|
| author | F. A. Cheldieva T. M. Reshetnyak A. A. Shumilova K. S. Nurbaeva M. V. Cherkasova A. M. Lila E. L. Nasonov |
| author_facet | F. A. Cheldieva T. M. Reshetnyak A. A. Shumilova K. S. Nurbaeva M. V. Cherkasova A. M. Lila E. L. Nasonov |
| author_sort | F. A. Cheldieva |
| collection | DOAJ |
| description | Introduction. The Global Antiphospholipid Syndrome Score (GAPSS) is a tool proposed to quantify the risk of clinical manifestations associated with antiphospholipid antibodies (aPL) and certain cardiovascular risk factors.Objective. To validate GAPSS in a cohort of patients with systemic lupus erythematosus in Russia.Material and methods. 115 patients with SLE were included in the study, including 51 (44%) patients with systemic lupus erythematosus (SLE) with antiphospholipid syndrome (APS), 14 (12%) – SLE with aPL, and 50 (44%) – SLE.Results. There was a history of thrombosis in 58 (50%) patients with 115, of them 14 (24%) had arterial thrombosis, 29 (50%) – venous, 15 (26%) – combined. Pregnancy against the background of the disease occurred in 43 women included in the study. Of them, 29 (67%) had obstetric pathology. Patients with thrombosis and obstetric pathology had a GAPSS score of 7.17±5.64, versus 4.48±4.55 without these manifestations (p=0.0003). There was a significant association between GAPSS levels and thrombosis – patients with thrombosis had a GAPSS of 7.31±5.70, those without thrombosis – 4.00±4.81 (p=0.001). GAPPS values were higher in arterial thrombosis compared to venous thrombosis (10.40±25.30 versus 5.82±5.28; p=0.01). GAPSS levels ≥6 and ≥10 were analyzed to select GAPSS values at which a high risk of recurrent thrombosis and/or obstetric pathology could be indicated. All GAPSS levels had a significant association with clinical manifestations of APS. The quality of GAPSS by ROC analysis showed an area under the curve (AUC) for GAPSS of 0.697.Conclusion. GAPSS can be used to assess the risk of recurrence or development of thrombosis and/or obstetric pathology in patients with SLE in the Russian Federation. The GAPSS ≥6 values should be used to stratify patients with SLE into high risk group for recurrence of vascular complications. Further prospective follow-up is needed to confirm the value of GAPSS. |
| format | Article |
| id | doaj-art-34f8ead4e6d14878ab149c2a524fc281 |
| institution | Kabale University |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| publishDate | 2022-11-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj-art-34f8ead4e6d14878ab149c2a524fc2812025-08-20T03:37:53ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922022-11-0160554655310.47360/1995-4484-2022-546-5532842Global antiphospholipid syndrome score (GAPSS) in patients with systemic lupus erythematosusF. A. Cheldieva0T. M. Reshetnyak1A. A. Shumilova2K. S. Nurbaeva3M. V. Cherkasova4A. M. Lila5E. L. Nasonov6V.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian FederationV.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)Introduction. The Global Antiphospholipid Syndrome Score (GAPSS) is a tool proposed to quantify the risk of clinical manifestations associated with antiphospholipid antibodies (aPL) and certain cardiovascular risk factors.Objective. To validate GAPSS in a cohort of patients with systemic lupus erythematosus in Russia.Material and methods. 115 patients with SLE were included in the study, including 51 (44%) patients with systemic lupus erythematosus (SLE) with antiphospholipid syndrome (APS), 14 (12%) – SLE with aPL, and 50 (44%) – SLE.Results. There was a history of thrombosis in 58 (50%) patients with 115, of them 14 (24%) had arterial thrombosis, 29 (50%) – venous, 15 (26%) – combined. Pregnancy against the background of the disease occurred in 43 women included in the study. Of them, 29 (67%) had obstetric pathology. Patients with thrombosis and obstetric pathology had a GAPSS score of 7.17±5.64, versus 4.48±4.55 without these manifestations (p=0.0003). There was a significant association between GAPSS levels and thrombosis – patients with thrombosis had a GAPSS of 7.31±5.70, those without thrombosis – 4.00±4.81 (p=0.001). GAPPS values were higher in arterial thrombosis compared to venous thrombosis (10.40±25.30 versus 5.82±5.28; p=0.01). GAPSS levels ≥6 and ≥10 were analyzed to select GAPSS values at which a high risk of recurrent thrombosis and/or obstetric pathology could be indicated. All GAPSS levels had a significant association with clinical manifestations of APS. The quality of GAPSS by ROC analysis showed an area under the curve (AUC) for GAPSS of 0.697.Conclusion. GAPSS can be used to assess the risk of recurrence or development of thrombosis and/or obstetric pathology in patients with SLE in the Russian Federation. The GAPSS ≥6 values should be used to stratify patients with SLE into high risk group for recurrence of vascular complications. Further prospective follow-up is needed to confirm the value of GAPSS.https://rsp.mediar-press.net/rsp/article/view/3221disease activityantiphospholipid syndromesystemic lupus erythematosusantiphospholipid antibodiesthrombosisobstetric pathology |
| spellingShingle | F. A. Cheldieva T. M. Reshetnyak A. A. Shumilova K. S. Nurbaeva M. V. Cherkasova A. M. Lila E. L. Nasonov Global antiphospholipid syndrome score (GAPSS) in patients with systemic lupus erythematosus Научно-практическая ревматология disease activity antiphospholipid syndrome systemic lupus erythematosus antiphospholipid antibodies thrombosis obstetric pathology |
| title | Global antiphospholipid syndrome score (GAPSS) in patients with systemic lupus erythematosus |
| title_full | Global antiphospholipid syndrome score (GAPSS) in patients with systemic lupus erythematosus |
| title_fullStr | Global antiphospholipid syndrome score (GAPSS) in patients with systemic lupus erythematosus |
| title_full_unstemmed | Global antiphospholipid syndrome score (GAPSS) in patients with systemic lupus erythematosus |
| title_short | Global antiphospholipid syndrome score (GAPSS) in patients with systemic lupus erythematosus |
| title_sort | global antiphospholipid syndrome score gapss in patients with systemic lupus erythematosus |
| topic | disease activity antiphospholipid syndrome systemic lupus erythematosus antiphospholipid antibodies thrombosis obstetric pathology |
| url | https://rsp.mediar-press.net/rsp/article/view/3221 |
| work_keys_str_mv | AT facheldieva globalantiphospholipidsyndromescoregapssinpatientswithsystemiclupuserythematosus AT tmreshetnyak globalantiphospholipidsyndromescoregapssinpatientswithsystemiclupuserythematosus AT aashumilova globalantiphospholipidsyndromescoregapssinpatientswithsystemiclupuserythematosus AT ksnurbaeva globalantiphospholipidsyndromescoregapssinpatientswithsystemiclupuserythematosus AT mvcherkasova globalantiphospholipidsyndromescoregapssinpatientswithsystemiclupuserythematosus AT amlila globalantiphospholipidsyndromescoregapssinpatientswithsystemiclupuserythematosus AT elnasonov globalantiphospholipidsyndromescoregapssinpatientswithsystemiclupuserythematosus |